The phenomenon of age-related loss of muscle mass and strength was named sarcopenia in 1988 by Rosenberg. Since then, sarcopenia has evolved to include the loss of muscle function in the definition. Sarcopenia has a high prevalence in specific clinical conditions and in the older population and can lead to significant morbidity, poor recovery from adverse events and ultimately, institutionalisation. In spite of the severe health care burden posed, the diagnosis and treatment of sarcopenia have yet to become standard care. Emerging consensus on definition and diagnosis by the international work groups on sarcopenia with tailored population-based cut-offs and growing evidence-based management options will facilitate the meeting of these needs.